{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:45:37Z","timestamp":1782215137399,"version":"3.54.5"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"24","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,23]]},"DOI":"10.1093\/eurheartj\/ehag059","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T12:58:58Z","timestamp":1769086738000},"page":"3132-3134","source":"Crossref","is-referenced-by-count":1,"title":["Long-term safety and efficacy of aficamten in the evolving era of myosin inhibition for obstructive hypertrophic cardiomyopathy"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6408-4667","authenticated-orcid":false,"given":"Luis R","family":"Lopes","sequence":"first","affiliation":[{"name":"St Bartholomew\u2019s Hospital, Barts Heart Centre , London ,","place":["UK"]},{"name":"Institute of Cardiovascular Science, University College London , 16\u201318 Westmoreland Street, London W1G 8PH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"2026062219563626600_ehag059-B1","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2026062219563626600_ehag059-B2","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026062219563626600_ehag059-B3","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2026062219563626600_ehag059-B4","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"2026062219563626600_ehag059-B5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026062219563626600_ehag059-B6","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"2026062219563626600_ehag059-B7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJMoa2504654","article-title":"Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy","volume":"393","author":"Garcia-Pavia","year":"2025","journal-title":"N Engl J Med"},{"key":"2026062219563626600_ehag059-B8","doi-asserted-by":"publisher","first-page":"102496","DOI":"10.1016\/j.jchf.2025.03.040","article-title":"Aficamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: 48-week results from FOREST-HCM","volume":"13","author":"Saberi","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026062219563626600_ehag059-B9","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1093\/eurheartj\/ehaf1085","article-title":"Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study","volume":"47","author":"Tower-Rader","year":"2026","journal-title":"Eur Heart J"},{"key":"2026062219563626600_ehag059-B10","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","article-title":"Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Garcia-Pavia","year":"2024","journal-title":"Eur Heart J"},{"key":"2026062219563626600_ehag059-B11","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1016\/j.jacc.2024.08.015","article-title":"Effect of aficamten on cardiac structure and function in obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM CMR substudy","volume":"84","author":"Masri","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026062219563626600_ehag059-B12","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/j.jacc.2024.08.002","article-title":"Impact of aficamten on echocardiographic cardiac structure and function in symptomatic obstructive hypertrophic cardiomyopathy","volume":"84","author":"Hegde","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026062219563626600_ehag059-B13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"2026062219563626600_ehag059-B14","doi-asserted-by":"publisher","first-page":"22501","DOI":"10.1038\/s41598-022-26889-2","article-title":"Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy","volume":"12","author":"Margara","year":"2022","journal-title":"Sci Rep"},{"key":"2026062219563626600_ehag059-B15","doi-asserted-by":"publisher","first-page":"e013418","DOI":"10.1161\/CIRCHEARTFAILURE.125.013418","article-title":"Efficacy and safety of aficamten in children and adolescents with obstructive hypertrophic cardiomyopathy: study design and rationale of CEDAR-HCM","author":"Kaski","year":"2025","journal-title":"Circ Heart Fail"},{"key":"2026062219563626600_ehag059-B16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41569-023-00853-7","article-title":"Detection of subclinical hypertrophic cardiomyopathy","volume":"20","author":"Joy","year":"2023","journal-title":"Nat Rev Cardiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/24\/3132\/67258983\/ehag059.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/24\/3132\/67258983\/ehag059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:56:43Z","timestamp":1782172603000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/24\/3132\/8509260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":16,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2026,3,6]]},"published-print":{"date-parts":[[2026,6,23]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag059","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,21]]},"published":{"date-parts":[[2026,3,6]]}}}